Trials / Completed
CompletedNCT02598505
Indacaterol in Heart Failure Patients: Any Role on Lung Fluid Regulation
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Centro Cardiologico Monzino · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purposes of this study are: 1. To confirm safety of Indacaterol in stable Heart Failure. 2. To determine whether beta 2 alveolar receptor stimulation by Indacaterol is able to ameliorate lung diffusion in heart Failure patients treated with beta blockers. 3. To compare the effects of Indacaterol in patients treated with a non-selective beta blocker (Carvedilol) and a beta 1-selective beta blocker (Bisoprolol).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Indacaterol | |
| DRUG | Placebo |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2016-11-01
- Completion
- 2016-11-01
- First posted
- 2015-11-06
- Last updated
- 2020-01-27
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT02598505. Inclusion in this directory is not an endorsement.